可治疗特征指导的哮喘管理:可行性研究
本研究为为期10周的单组队列研究,纳入29例医生诊断哮喘、ACQ-5>1且过去一年至少一次急性发作的患者,采用生物标志物指导的方案化治疗。干预可接受,ACQ-5改善-1.0单位,但65%患者10周后仍控制不佳,需扩展特征评估。
要点
- 方案化可治疗特征管理在非严重哮喘门诊患者中可行且可接受。
- 靶向2型炎症和气流受限不足以控制多数患者哮喘。
- 研究期间41%患者曾接受持续口服糖皮质激素治疗。
核心结论
- 方案化可治疗特征管理对参与者可接受,与显著临床获益相关,完整RCT似乎可行。
- 靶向2型炎症和气流受限不足以控制多数患者哮喘,尽管存在明显全身糖皮质激素暴露。
研究设计与样本
- 为期10周的单组队列研究,招募因COVID-19相关困难在14个月后停止,共29/50例参与者。
- 参与者有医生诊断的哮喘、ACQ-5评分>1且过去一年至少一次急性发作。
主要发现
- 招募率:受邀参与者中29/118(25%)参与(95%CI 17至33)。
- 24/26(92%)参与者认为干预可接受并愿意参与未来研究。
- 10周后65%患者仍控制不佳(ACQ-5>1),需要扩展评估。
- 参与者平均(SD)评估了13个特征中的4.8(2.3)个。
- 研究期间ACQ-5改善-1.0(0.3至1.8)单位,支气管舒张后气流受限从59%降至35%。
临床怎么用
- 在非严重哮喘门诊患者中,可考虑采用方案化可治疗特征管理,但需注意多数患者仍需扩展评估。
局限性
- 招募因COVID-19相关困难提前终止,样本量较小。
- 单组队列研究,无法确定干预的对照效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Treatable trait-based personalised medicine improves outcomes in severe asthma clinics. We assessed the feasibility of a randomised controlled trial (RCT) of protocolised treatable trait-guided asthma management in patients not under a severe asthma clinic. METHODS: Ten week single-group cohort study. Participants had a doctor's diagnosis of asthma, Asthma Control Questionnaire-5 (ACQ-5) score > 1, and ≥ 1 exacerbation in the last year. INTERVENTION: biomarker-guided asthma medication according to a protocolised algorithm, targeting traits of type-2 inflammation and airflow obstruction. Feasibility outcomes: recruitment rates, acceptability of intervention, willingness to enrol in an RCT, need for 'extended' trait assessment after 10 weeks, and estimation of trait prevalence. RESULTS: Recruitment ceased with 29/50 participants after 14 months due to difficulties associated with COVID-19. Recruitment rate: 29/118 (25%) of those invited to participate (95% CI 17 to 33). 24/26 (92%) participants found the intervention acceptable and were willing to participate in a future study. After 10 weeks, 65% remained not well controlled (ACQ-5 > 1) and would have required the 'extended' assessment. Participants had a mean (SD) 4.8 (2.3) of 13 traits assessed. ACQ-5 improved during the study by -1.0 (0.3 to 1.8) units, and post-bronchodilator airflow limitation reduced from 59% of participants to 35%. 12/29 (41%) participants received continuous oral corticosteroids at some point during the study. CONCLUSION: Protocolised treatable trait management was acceptable to participants, associated with significant clinical benefit, and a full RCT appears feasible. Targeting type-2 inflammation and airflow obstruction was insufficient to control asthma in the majority of patients, despite marked systemic corticosteroid exposure. TRIAL REGISTRATION: ACTRN12620000935932.
引用
- Fingleton, McLachlan, Sparks, et al. Treatable Trait Guided Asthma Management: A Feasibility Study. Respirology. 2025. PMID: 40074003. doi:10.1111/resp.70016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。